Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 20/20 | 0.61 |
| ▸ | SOAT1 | P35610 | 13/20 | 0.61 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249005 | 0.91 | DGAT1 (0.66) | DGAT1SOAT1DGAT2 | |
| SCHEMBL2241763 | 0.91 | DGAT1 (0.66) | DGAT1SOAT1DGAT2 | |
| SCHEMBL2241760 | 0.91 | DGAT1 (0.66) | DGAT1SOAT1DGAT2 | |
| SCHEMBL13754640 | 0.89 | DGAT1 (0.69) | DGAT1SOAT1DGAT2 | |
| SCHEMBL13754642 | 0.89 | DGAT1 (0.69) | DGAT1SOAT1DGAT2 | |
| SCHEMBL13748081 | 0.89 | DGAT1 (0.63) | DGAT1SOAT1DGAT2 | |
| SCHEMBL1399605 | 0.89 | DGAT1 (0.63) | DGAT1SOAT1DGAT2 | |
| SCHEMBL14336182 | 0.86 | DGAT1 (0.59) | DGAT1SOAT1DGAT2 | |
| SCHEMBL13747427 | 0.86 | DGAT1 (0.59) | DGAT1SOAT1DGAT2 | |
| SCHEMBL2243000 | 0.83 | DGAT1 (0.66) | DGAT1SOAT1DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035417-B1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | DGAT1, ACAT1, DGAT2 | DGAT1 1/4885SOAT1 5/4885DGAT2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.